Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the
appointment of Bruce L.A. Carter, Ph.D. to its Board of Directors. Dr.
Carter will also serve as a member of the Compensation and the
Nominating and Corporate Governance Committees. The Board also announced
today the resignation of Helmut M. Schuhsler, Ph.D. as a director.
“Dr. Carter’s combination of scientific expertise and operational
experience in the healthcare field will be invaluable to Enanta as we
continue to research infectious disease areas and advance our lead
compounds,” stated Jay R. Luly, Ph.D. President and Chief Executive
Officer. “I would also like to thank Helmut for his leadership, guidance
and dedication to Enanta, which we have benefited from since he first
joined our Board in 1998. I wish him continued success.”
“It is a privilege to join Enanta’s Board at this exciting time in the
company’s history,” commented Bruce L.A. Carter, Ph.D. “I look forward
to my service on the Board and to contributing to the company’s future
success.”
Dr. Carter has extensive experience in the pharmaceutical industry
including positions as an executive and director. He currently serves as
a director of Dr. Reddy’s Ltd., Immune Design Corp, Xencor Inc. and
Regulus Therapeutics and is currently an Affiliate Professor, Department
of Biochemistry at the University of Washington, Seattle, Washington.
Dr. Carter served as Executive Chairman of Immune Design Corp. from 2009
to 2011. From 2000 to 2009, he held executive management positions at
ZymoGenetics, Inc., where he served as President and Chief Executive
Officer until 2009, and continued as Chairman of the Board until 2010,
when the company was acquired by Bristol Myers Squibb. He worked at Novo
Nordisk from 1994 to 2000 as Corporate Executive Vice President and
Chief Scientific Officer. Previously he was at ZymoGenetics, which was
acquired by Novo Nordisk, where he served as their President from 1988
to 1994 and as Vice President Research and Development from 1986 to
1988. Dr. Carter began his career at G.D. Searle & Co. Ltd. where from
1982 to 1986 he was Head of Molecular Genetics.
Dr. Carter received a B.Sc. with Honors in Botany from the University of
Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth
College, University of London.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs in the
infectious disease field. Enanta is discovering, and in some cases
developing, novel inhibitors designed for use against the hepatitis C
virus (HCV). These inhibitors include members of the direct acting
antiviral (DAA) inhibitor classes – protease (partnered with AbbVie),
NS5A (partnered with Novartis) and nucleotide polymerase – as well as a
host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Additionally, Enanta has created a new class of
antibiotics, called Bicyclolides, for the treatment of multi-drug
resistant bacteria, with a focus on developing an intravenous and oral
treatment for hospital and community MRSA (methicillin-resistant Staphylococcus
aureus) infections.
Copyright Business Wire 2013